The development of precision medicine for cancer requires accurately quantifying the dynamics of tumor evolution. Two reasons this can be difficult are the limited number of times we can observe the tumor and intra-tumor heterogeneity that is difficult to completely characterize. In this presentation, I will first discuss an approach that uses high throughput drug screens to quantify the heterogeneity present in patient tumor samples. This information can then be used to guide future treatment decisions. I will next discuss the use of the site frequency spectrum (SFS) to learn vital information about a tumor sample based on observations at a single time point.